MedTrace Logo

Single Ascending Doses of HER-096 in Healthy Subjects

NCT05915247 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-10-27

No results posted yet for this study

Summary

This study evaluates the safety and tolerability of HER-096 in healthy volunteer subjects by comparing the effects of active study treatment HER-096 to placebo (0.9% physiological saline). In addition, the pharmacokinetic profile of HER-096 in humans will be investigated. The investigational medicinal products will be administered as a single dose by subcutaneous injection.

Conditions

  • Parkinson Disease

Interventions

DRUG

HER-096

Administered as a single dose via s.c. injection

DRUG

Placebo

Administered as a single dose via s.c. injection

Sponsors & Collaborators

  • Clinical Research Services Turku - CRST Oy

    collaborator UNKNOWN

  • Herantis Pharma Plc.

    lead INDUSTRY

Principal Investigators

  • Aleksi Tornio, MD · Clinical Research Services Turku - CRST Oy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-29
Primary Completion
2023-09-29
Completion
2023-09-29

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05915247 on ClinicalTrials.gov